share_log

康方生物:自願公告 - 卡度尼利一線治療宮頸癌的III期臨床試驗(AK104 -303)的期中分析達到無進展生存期(PFS)主要終點

AKESO: VOLUNTARY ANNOUNCEMENT - AK104-303, A PHASE III TRIAL OF CADONILIMAB REACHED PROGRESSION-FREE-SURVIVAL (PFS) PRIMARY ENDPOINT AT INTERIM ANALYSIS FOR FIRST LINE TREATMENT OF CERVICAL CANCER

香港交易所 ·  Nov 22, 2023 18:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more